• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study.

作者信息

Kaplan Gilaad G, Ma Christopher, Charlton Carmen, Kanji Jamil N, Tipples Graham, Sharifi Nastaran, Herauf Michelle, Coward Stephanie, Ingram Richard J M, Hracs Lindsay, Benchimol Eric I, Panaccione Remo

机构信息

Division of Gastroenterology & Hepatology, University of Calgary, Calgary, Alberta, Canada

Division of Gastroenterology & Hepatology, University of Calgary, Calgary, Alberta, Canada.

出版信息

Gut. 2022 Jun;71(6):1229-1231. doi: 10.1136/gutjnl-2021-325238. Epub 2021 Aug 2.

DOI:10.1136/gutjnl-2021-325238
PMID:34340997
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9120372/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6eb9/9120372/9c4431948b3d/gutjnl-2021-325238f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6eb9/9120372/9c4431948b3d/gutjnl-2021-325238f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6eb9/9120372/9c4431948b3d/gutjnl-2021-325238f01.jpg

相似文献

1
Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study.炎症性肠病患者对新冠病毒2的抗体反应随时间减弱：一项血清学监测队列研究。
Gut. 2022 Jun;71(6):1229-1231. doi: 10.1136/gutjnl-2021-325238. Epub 2021 Aug 2.
2
A Seroprevalence Study of Anti-SARS-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease during the Second Wave of the COVID-19 Pandemic in Italy.意大利第二波新冠疫情期间炎症性肠病患者抗SARS-CoV-2抗体血清流行率研究
Medicina (Kaunas). 2021 Oct 1;57(10):1048. doi: 10.3390/medicina57101048.
3
Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease.炎症性肠病中 SARS-CoV-2 感染的低流行率。
Eur Rev Med Pharmacol Sci. 2021 Mar;25(5):2418-2424. doi: 10.26355/eurrev_202103_25283.
4
Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy.生物治疗的炎症性肠病患者中 SARS-CoV2 的血清阳性率。
J Crohns Colitis. 2021 May 4;15(5):864-868. doi: 10.1093/ecco-jcc/jjaa237.
5
Antibody Response 3 Months After 2-Dose SARS-CoV-2 mRNA Vaccination in Patients With Inflammatory Bowel Disease.炎症性肠病患者接种两剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗3个月后的抗体反应
Am J Gastroenterol. 2022 May 1;117(5):798-801. doi: 10.14309/ajg.0000000000001668. Epub 2022 Jan 29.
6
Inflammatory bowel disease and SARS-CoV-2 pandemic: current knowledge and recommendations.炎症性肠病与 SARS-CoV-2 大流行：现有知识和建议。
Scand J Gastroenterol. 2021 Jun;56(6):656-660. doi: 10.1080/00365521.2021.1902561. Epub 2021 Mar 25.
7
T Cell Response After SARS-CoV-2 Vaccination in Immunocompromised Patients with Inflammatory Bowel Disease.免疫功能低下的炎症性肠病患者接种 SARS-CoV-2 疫苗后的 T 细胞反应。
J Crohns Colitis. 2022 Feb 23;16(2):251-258. doi: 10.1093/ecco-jcc/jjab147.
8
Are Patients With Inflammatory Bowel Disease at an Increased Risk of Developing SARS-CoV-2 than Patients Without Inflammatory Bowel Disease? Results From a Nationwide Veterans' Affairs Cohort Study.炎症性肠病患者感染 SARS-CoV-2 的风险是否高于非炎症性肠病患者？一项全国退伍军人事务队列研究的结果。
Am J Gastroenterol. 2021 Apr;116(4):808-810. doi: 10.14309/ajg.0000000000001012.
9
Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against SARS-CoV-2.炎症性肠病与针对 SARS-CoV-2 的抗体血清阳性率升高有关。
Pol Arch Intern Med. 2021 Mar 30;131(3):226-232. doi: 10.20452/pamw.15796. Epub 2021 Feb 5.
10
Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD clinics?炎症性肠病医疗专业人员中的抗SARS-CoV-2抗体检测：我们目前能否提供无新冠病毒的炎症性肠病诊所？
Scand J Gastroenterol. 2020 Aug;55(8):917-919. doi: 10.1080/00365521.2020.1791244. Epub 2020 Jul 14.

引用本文的文献

1
The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologics.IBD 患者感染 COVID-19 的风险因居住在城市而增加，且与疾病活动或静脉内生物制剂无关。
Front Immunol. 2023 Aug 28;14:1243898. doi: 10.3389/fimmu.2023.1243898. eCollection 2023.
2
Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease.炎症性肠病患者对三剂严重急性呼吸综合征冠状病毒2疫苗接种的血清学反应。
Gut. 2023 Apr;72(4):802-804. doi: 10.1136/gutjnl-2022-327440. Epub 2022 May 23.
3
Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era.

本文引用的文献

1
Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.加拿大艾伯塔省 COVID-19 大流行前两波期间 SARS-CoV-2 抗体的预疫苗阳性率。
Microbiol Spectr. 2021 Sep 3;9(1):e0029121. doi: 10.1128/Spectrum.00291-21. Epub 2021 Aug 18.
2
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.抗 SARS-CoV-2 抗体反应在接受英夫利昔单抗治疗的 IBD 患者中减弱。
Gut. 2021 May;70(5):865-875. doi: 10.1136/gutjnl-2021-324388. Epub 2021 Mar 22.
3
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
疫苗时代加拿大献血者中 SARS-CoV-2 血清流行率的变化模式。
Microbiol Spectr. 2022 Apr 27;10(2):e0033922. doi: 10.1128/spectrum.00339-22. Epub 2022 Apr 12.
4
Circulating IgG Levels in SARS-CoV-2 Convalescent Individuals in Cyprus.塞浦路斯新冠康复者体内的循环免疫球蛋白G水平
J Clin Med. 2021 Dec 15;10(24):5882. doi: 10.3390/jcm10245882.
5
Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Epidemiology-The Trends of Disease Over Time.加拿大克罗恩病与结肠炎协会《2021年新冠疫情对加拿大炎症性肠病的影响：流行病学——疾病随时间的趋势》
J Can Assoc Gastroenterol. 2021 Nov 5;4(Suppl 2):S20-S26. doi: 10.1093/jcag/gwab029. eCollection 2021 Dec.
6
Gastrointestinal manifestations and possible mechanisms of COVID-19 in different periods.新型冠状病毒肺炎不同时期的胃肠道表现及可能机制
J Dig Dis. 2021 Dec;22(12):683-694. doi: 10.1111/1751-2980.13065. Epub 2021 Dec 12.
7
Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα.抗 TNF-α 治疗的炎症性肠病患者对 COVID-19 mRNA 疫苗的血清学反应较低。
Gastroenterology. 2022 Feb;162(2):454-467. doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28.
对感染后长达 8 个月的 SARS-CoV-2 进行免疫记忆评估。
Science. 2021 Feb 5;371(6529). doi: 10.1126/science.abf4063. Epub 2021 Jan 6.
4
Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy.生物治疗的炎症性肠病患者中 SARS-CoV2 的血清阳性率。
J Crohns Colitis. 2021 May 4;15(5):864-868. doi: 10.1093/ecco-jcc/jjaa237.
5
Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity.五种用于检测 SARS-CoV-2 抗体的免疫分析方法的分析和临床性能与中和活性的比较。
EBioMedicine. 2020 Dec;62:103101. doi: 10.1016/j.ebiom.2020.103101. Epub 2020 Nov 4.
6
SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California.加利福尼亚北部炎症性肠病患者中2019冠状病毒病的严重急性呼吸综合征冠状病毒2检测、患病率及预测因素
Gastroenterology. 2020 Sep;159(3):1141-1144.e2. doi: 10.1053/j.gastro.2020.05.009. Epub 2020 May 7.